Table 2.

Important clinical data and technical details of the ⁶⁸Ga-PSMA ligand PET/CT examination

Clinical Notes: In patients with primary PC the following information should be included:

– date of diagnosis

– type of verification of diagnosis (biopsy results, time of biopsy, Gleason score)

– current PSA value

– previous imaging results

– relevant further diagnoses (e.g. renal insufficiency, other malignancies)

In patients with biochemical recurrence additional information is necessary:

– previous surgery and therapy (e.g. antihormonal treatment, radiation therapy, chemotherapy)

– initial PSA value, PSA nadir, facultative information on PSA-kinetics

Technical Details:

– exact name of the radiopharmaceutical agent and applied activity, time of scan start post injection, number of bed positions and time per bed position, body weight

– Information concerning medication administered as preparation of the PET scan (e.g. furosemide)

– CT-protocol: low-dose or/and diagnostic CT, contrast agent application (oral/rectal/ intravenous, information on concentrations and volumes, native, arterial, portalvenous), scanned portion of the body